MedTrace Logo

Growth And Safety Outcomes In Infants With Cow´s Milk Protein Allergy (CMPA) Fed A Novel Extensively Hydrolyzed Formula (eHF)

NCT07711938 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 410

Last updated 2026-07-17

No results posted yet for this study

Summary

Growth and safety Outcomes in infants with CMPA fed a novel extensively hydrolyzed formula.

Conditions

  • Cow Milk Protein Allergy

Interventions

DIETARY_SUPPLEMENT

New generation eHF

New generation of a whey-based eHF formula intended for the dietary management of infants with CMPA.

DIETARY_SUPPLEMENT

Commercial eHF

Commercial whey-based eHF formula intended for the dietary management of infants with CMPA.

Sponsors & Collaborators

  • Société des Produits Nestlé (SPN)

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
29 Days
Max Age
22 Weeks
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-01
Primary Completion
2028-07-31
Completion
2029-05-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07711938 on ClinicalTrials.gov